Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Treasury Shares (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Treasury Shares data on record, last reported at $6.0 million in Q4 2025.

  • For Q4 2025, Treasury Shares fell 0.79% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $6.0 million, down 0.79%, while the annual FY2025 figure was $6.0 million, 0.79% down from the prior year.
  • Treasury Shares reached $6.0 million in Q4 2025 per ARQT's latest filing, down from $6.2 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $7.2 million in Q1 2025 and bottomed at $310068.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $3.5 million, with a median of $2.9 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: skyrocketed 370.33% in 2022, then decreased 4.59% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $335196.0 in 2021, then surged by 370.33% to $1.6 million in 2022, then surged by 85.83% to $2.9 million in 2023, then skyrocketed by 106.69% to $6.1 million in 2024, then decreased by 0.79% to $6.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $6.0 million in Q4 2025, $6.2 million in Q3 2025, and $6.6 million in Q2 2025.